PLAN DE BENEFICIO AL PACIENTE que favorece en la adherencia y cumplimiento del Tx
Telmisartán 80 mg
Telydalt 80mg
Telmisartán 80 mg + Hidroclorotiazida 12,5 mg
Telmisartán 80 mg + Hidroclorotiazida 25 mg
Telydalt Plus 80 / 12.5 mg
Telydalt Plus 80 / 25 mg
Telmisartán 80 mg + Amlodipino 5 mg
Telmisartán 80 mg + Amlodipino 10 mg
Telydalt Duo 80 / 5 mg
Telydalt Duo 80 / 10 mg
McInnes G. / Journal of the American Society of Hypertension 2008; :S16-S22
Bakris, G. Burgess, E., Weir, M., & Koval, S. (2008). Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney International, 74(3). h-ttp-s:/-/doi-.org-/10.1038/ki.2008.204
Han, L., Shen, W. J., Bittner, S., Kraemer, F.B., & Azhar, S. (2017). PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-PPAR β/δ and PPAR-y. In Future Cardiology(Vol 13, Issue 3). h-ttp-s:/-/doi-.org-/10.2227/fca-2017-0019
Penna-de-Carvalho, A., Graus-Nunes, F., Rabelo-Andrade, J., Mandarim-de-Lacerda, C.A., & Souza-Mello, V. (2014). Enhanced pan-peroxisome proliferator-activated receptor gene and protein expression in adipose tissue of diet-induced obese mice treated with telmisartan. Experimental Physiology, 99(12), 1663-1678. h-ttp-s:/-/doi-.org-/10.1113/expphysiol.2014.081596
Burnier, M. (2009). Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population? Journal of International Medical Research, 37(6), 1662-1679. h-ttp-s:/-/doi-.org-/10.1177/147323000903700602
Tuñón, J., Ruiz-Ortega, M., Luis Martín-Ventura, J., Tarín, N., & Egido, J. (2007). Efectos pleiotrópicos de telmisartán en el paciente diabético. Revista Española de Cardiología Suplementos, 7(1), 23A-30A. h-ttp-s:/-/doi-.org-/10.1016/S1131-3587(07)75232-9
Derosa, G., Fogari, E., D’Angelo, A., Cicero, A. F. G., Salvadeo, S. A. T., Ragonesi, P.D., Ferrari, I., Gravina, A., Fassi, R., &Fogari, R. (2007). Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. Journal of clinical Pharmacy and Therapeutics, 32(3), 261-268. h-ttp-s:/-/doi-.org-/10.1111/j.1365-2710.2007.00820.x
